Please ensure Javascript is enabled for purposes of website accessibility

Why Simulations Plus Stock Soared 35.9% in July

By Steve Symington – Aug 8, 2019 at 8:52PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The modeling and simulation software leader rallied on news of strong quarterly results and an exciting partnership.

What happened

Shares of Simulations Plus (SLP -1.60%) jumped 35.9% in July, according to data from S&P Global Market Intelligence, after the specialized modeling and simulation software company announced strong results for its fiscal third quarter ended May 31, 2019. The company also entered into an intriguing new collaboration agreement with the U.S. Food and Drug Administration (FDA).

On the former, Simulations Plus stock jumped more than 6% on July 11, 2019 alone, the first trading day after the company's quarterly report hit the wires. In it, Simulations Plus revealed quarterly revenue had climbed 16.2% year over year, to $9.9 million. That translated to a 20.1% increase in net income, to $2.9 million, and an 18.8% gain in earnings per share, to $0.16. Analysts, on average, were expecting earnings of just $0.14 per share on slightly lower revenue.

Man on ladder drawing yellow stock chart on a brick wall indicating steep gains.


So what

Simulations Plus CEO Shawn O'Connor lauded "significant progress" in the company's strategic initiatives put into place at the start of the fiscal year.

"These initiatives include investments in sales and marketing strategies to take advantage of increasing adoption of modeling and simulation applications in the pharmaceutical market," O'Connor elaborated. "In addition, we have accelerated our efforts to attract scientific talent to increase our services capacity [and] initiated efforts to increase our local presence in global markets."

If that wasn't enough, the following week, Simulations Plus announced a new five-year research collaboration with the FDA's Center for Veterinary Medicine. Under the partnership, the FDA will use Simulations Plus' GastroPlus software with both in vitro and in vivo data to investigate how bioequivalence of certain locally acting drugs can be evaluated in canines without requiring clinical endpoint trials. If the FDA's efforts are successful, Simulations Plus added, "a framework can be provided to support these approaches for other drugs."

Now what

As it stands, it's encouraging to see Simulations Plus striking new partnerships that could not only result in groundbreaking scientific advancements but also effectively highlight extended-use cases of its software solutions. Coupled with the company's latest quarterly update, that seems to show the early fruits of Simulations Plus' efforts to expand its global reach, and it's no surprise the stock popped last month in response.

Steve Symington has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Simulations Plus, Inc. Stock Quote
Simulations Plus, Inc.
$50.33 (-1.60%) $0.82

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/07/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.